Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11911736 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL5243913 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11080842 | 0.98 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Hydrochloric Acid SCHEMBL21767824 | 0.81 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL3802121 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL457278 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL378481 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL3802117 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL11911741 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4710252 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | claimed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8283474-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| US-8263782-B2 | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
| EP-1917013-B1 | USE OF AZABICYCLO HEXANE DERIVATIVES | GLAXO GROUP LTD (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-7855298-B2 | Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-12-21 | — | — | US | disclosed |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-06-17 | — | — | US | disclosed |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1904059-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007013936-A2 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2007-01-25 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20100152195-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20100160336-A1 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors | DRD3, DRD1, DRD2 | SLC6A2 654/4885SLC6A4 660/4885SLC6A3 26/4885 |
| US-20090036461-A1 | Use of Azabicyclo Hexane Derivatives | ADH1C, PKD1, HTT | SLC6A2 894/4885SLC6A4 358/4885SLC6A3 30/4885 |
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | SLC6A2 360/4885SLC6A4 395/4885SLC6A3 18/4885 |
| US-20070021488-A1 | Method for treating nervous system disorders and conditions | AVPR1B, AVPR2, AVPR1A | SLC6A2 33/4885SLC6A4 145/4885SLC6A3 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.